"Loneliness and persistence are the necessary paths to success. Six pharmaceutical enterprises including Peking University Pharmaceutical, relying on innovation and focus, have continuously made breakthroughs in their respective fields, demonstrating the infinite possibilities of the pharmaceutical industry. On the investment road, only by enduring loneliness can you keep prosperity."

Written in the front

1. Endure loneliness, and success will be near.

When you are in the process, when everyone does not understand you and you feel extremely lonely, can you persist? Others act on feelings, while you are silently learning and improving. This is inherently lonely, but if you can get through it, success is probably not far away.

2. Tolerate loneliness, and hold onto prosperity.

Many times, when the market is good and others' stocks keep rising, but yours shows no improvement, do you waver? The road to success is lonely, and you need to be able to tolerate it.

3. Get through pain, and adapt to the market.

No matter what you do, you will always encounter difficulties and setbacks. It will never be plain sailing. Generally, pain will lead to two extremes: one is the negative side—listlessness and giving up; the other is the positive side—constantly overcoming and facing them. Once you get through the pain, you will find everything going more and more smoothly.

The First Enterprise: Peking University Pharmaceutical

Peking University Pharmaceutical upholds the core values of "Innovation, Responsibility, Trust, and Diligence" and takes "a raw material and preparation integrated imitation-innovation pharmaceutical technology enterprise" as its strategic positioning. It focuses on the development of the pharmaceutical industry around three core fields: "anti-infection, analgesics, and psychotropic drugs". At present, it has 166 drug approvals and 13 first generic drug approvals, with rich production lines such as injections, capsules, tablets, granules, and oral liquids. The company has established a technical system integrating innovative drugs, improved innovative drugs, and generic drugs, and has carried out more than 100 R&D projects. It has undertaken many key projects such as the National Key Torch Program, the 12th Five-Year Plan for Major New Drug Creation, and municipal-level science and technology plans, providing strong support for the research of the company's new products, new processes, and consistency evaluation projects.

The Second Enterprise: Shanghai Kaibao

The company adheres to the road of joint development through industry-university-research cooperation. Traditional Chinese medicine (TCM) is a treasure of the Chinese nation. The company's R&D focuses on innovative TCM drugs, while launching classic famous prescriptions, laying out in-hospital preparations, and developing health products with both medicinal and edible values. It is accelerating the research and development of new indications for Tanreqing, continuing to introduce new products, and striving to achieve the goal of based on TCM and laying out multiple pipelines.

The Third Enterprise: Zhongguancun

The main businesses of Beijing Zhongguancun Science & Technology Development (Holding) Co., Ltd. include biomedicine and health products, elderly care and medical services, commercial concrete, and other businesses. Its product Phencynonate Hydrochloride Tablets (Feisailuo) is a national Class I new drug and is currently an advanced drug in the global "motion sickness" field.

The Fourth Enterprise: Ruikang Pharmaceutical

In terms of terminal product R&D, this sector has independently developed intelligent equipment for TCM liquefaction, which will further research and produce liquefied medicinal and edible foods, health products, or TCM medicines. At the same time, this sector has cooperated with relevant medical experts from Guangdong Pharmaceutical University to jointly develop FTZ concentrated pills, a new TCM drug for the treatment of non-alcoholic hepatic steatosis, which has entered the Phase II clinical stage during the reporting period.

The Fifth Enterprise: Jinhua Co., Ltd.

The main business of Jinhua Enterprise (Group) Co., Ltd. is the R&D, production, and sales of drugs. Its main product, Artificial Tiger Bone Powder, is made from tiger bones (with components close to those of natural tiger bones). It is the world's only natural tiger bone substitute and has been selected as a national Class I new drug.

The Sixth Enterprise: Neptunus Bioengineering

In the field of pharmaceutical R&D, the company will continue to strengthen the construction of Neptunus innovative drug and generic drug R&D platforms. At the same time, it will continue to improve its independent innovation and development capabilities for differentiated layout. In terms of innovative drug R&D, it will focus on fields such as small-molecule chemical innovative drugs, biological agents, improved innovative drugs, TCM and natural medicines, and marine drugs, and develop new drugs with significant clinical application value.

All the above contents are personal opinions and do not constitute decision-making suggestions. The stock market is risky, and entering the market requires caution!